Lunsumio 30 mg/30 mL (1 mg/mL) injection Images
Generic Name: mosunetuzumab
This medication has been identified as Lunsumio 30 mg/30 mL (1 mg/mL) injection. It is supplied by Genentech, Inc.
Lunsumio is used in the treatment of Follicular Lymphoma and belongs to the drug class bispecific T-cell engagers (BiTE). Lunsumio 30 mg/30 mL (1 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Lunsumio
- Generic Name
- mosunetuzumab
- Strength
- 30 mg/30 mL (1 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Bispecific T-cell engagers (BiTE)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0142
More about Lunsumio (mosunetuzumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
